Insights

Growing Market Presence With a revenue range of 25 million to 50 million and ongoing product launches such as the pEGASUS HPC stent, WallabyPhenox demonstrates a strong growth trajectory and a expanding product portfolio that offers numerous sales opportunities in neurovascular treatments.

Recent Acquisition The acquisition by Wallaby Medical for 528 million USD positions WallabyPhenox as part of a larger global entity, providing opportunities to leverage increased resources and expanded distribution channels for advanced neurovascular devices.

Innovation Leadership Being recognized as one of Germany's top 500 most innovative companies highlights the company's focus on cutting-edge technology, which can be a key selling point when engaging healthcare providers seeking the latest neurovascular treatment solutions.

Strategic Expansion The hiring of a new CEO and increased presence at major industry congresses indicate a strategic focus on global expansion and market penetration, presenting opportunities to introduce new and innovative treatment products to international clients.

Targeted Product Offering The company’s portfolio of devices such as flow diverters and thrombectomy systems addresses complex neurovascular conditions, allowing sales teams to target specialized endovascular specialists and hospitals focusing on stroke treatment and aneurysm management.

Similar companies to WallabyPhenox

WallabyPhenox Tech Stack

WallabyPhenox uses 8 technology products and services including LinkedIn Ads, RSS, Open Graph, and more. Explore WallabyPhenox's tech stack below.

  • LinkedIn Ads
    Advertising
  • RSS
    Content Management System
  • Open Graph
    Content Management System
  • jQuery
    Javascript Libraries
  • OWL Carousel
    Javascript Libraries
  • All in One SEO
    Search Engines
  • WP Job Openings
    Web Platform Extensions
  • Apache
    Web Servers

WallabyPhenox's Email Address Formats

WallabyPhenox uses at least 2 format(s):
WallabyPhenox Email FormatsExamplePercentage
First.Last@phenox.infoJohn.Doe@phenox.info
100%
FLast@phenox.netJDoe@phenox.net
100%

Frequently Asked Questions

What is WallabyPhenox's phone number?

Minus sign iconPlus sign icon
You can contact WallabyPhenox's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is WallabyPhenox's official website and social media links?

Minus sign iconPlus sign icon
WallabyPhenox's official website is phenox.net and has social profiles on LinkedIn.

What is WallabyPhenox's NAICS code?

Minus sign iconPlus sign icon
WallabyPhenox's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does WallabyPhenox have currently?

Minus sign iconPlus sign icon
As of December 2025, WallabyPhenox has approximately 213 employees across 4 continents, including EuropeNorth AmericaAsia. Key team members include Chief Technology Officer And Bod Member: E. B.Vice President Corporate Innovation & Strategy: H. M.Vice President Of Sales: M. F.. Explore WallabyPhenox's employee directory with LeadIQ.

What industry does WallabyPhenox belong to?

Minus sign iconPlus sign icon
WallabyPhenox operates in the Medical Equipment Manufacturing industry.

What technology does WallabyPhenox use?

Minus sign iconPlus sign icon
WallabyPhenox's tech stack includes LinkedIn AdsRSSOpen GraphjQueryOWL CarouselAll in One SEOWP Job OpeningsApache.

What is WallabyPhenox's email format?

Minus sign iconPlus sign icon
WallabyPhenox's email format typically follows the pattern of First.Last@phenox.info. Find more WallabyPhenox email formats with LeadIQ.

When was WallabyPhenox founded?

Minus sign iconPlus sign icon
WallabyPhenox was founded in 2005.

WallabyPhenox

Medical Equipment ManufacturingNorth Rhine-westphalia, Germany201-500 Employees

Since its founding in 2005, phenox has been dedicated to developing innovative, breakthrough and clinically proven technologies and solutions for the treatment of neurovascular diseases. phenox's products are used by endovascular specialists to treat ischemic and hemorrhagic stroke.

The company offers a growing portfolio of innovative treatment options, including the primary interventional technologies used today. The product portfolio comprises the Mechanical Thrombectomy System pRESET, the p64, p48 MW and p64 MW Flow Diverters for the treatment of complex intracranial aneurysms and dissections as well as the pCONUS Implant for the treatment of complex, wide-neck bifurcation aneurysms.

The specially developed HPC Technology (Hydrophilic Polymer Coating) for aneurysm treatment products leads to a reduction in the thrombogenicity of the implant surface and thus to an increased patient safety.

Since 2020 phenox has also been the exclusive distributor of the Avenir Coiling System developed in California (USA) by Wallaby Medical. 

In 2022, Wallaby Medical, a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, announced that it has acquired phenox GmbH, including phenox’s femtos GmbH. This acquisition then lead to rebranding of previously phenox GmbH to WallabyPhenox.

Visit our website for further information about phenox and our products: https://www.phenox.net/

Imprint: https://phenox.net/international/imprint/

Section iconCompany Overview

Phone number
Website
phenox.net
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
2005
Employees
201-500

Section iconFunding & Financials

  • $25M$50M

    WallabyPhenox's revenue is estimated to be in the range of $25M$50M

Section iconFunding & Financials

  • $25M$50M

    WallabyPhenox's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.